This is a preview of subscription content, log in via an institution to check access.
Notes
The study was funded by Grünenthal GmbH.
Reference
Ruggeri M, et al. Cost-Effectiveness Analysis of Tapentadol Versus Oxycodone/Naloxone in both Branded and Generic Formulations in Patients with Musculoskeletal Pain. Clinical Drug Investigation : 15 Sep 2021. Available from: URL: https://doi.org/10.1007/s40261-021-01074-x
Rights and permissions
About this article
Cite this article
Extended-release tapentadol cost effective vs branded and generic oxycodone/naloxone in Italy. PharmacoEcon Outcomes News 888, 11 (2021). https://doi.org/10.1007/s40274-021-08061-y
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-021-08061-y